Heron Therapeutics Takes Shot at FDA After CRL Stalls Anti-Pain Treatment

Drug Industry Daily
A A
Heron Therapeutics on Wednesday said they were sandbagged by federal regulators who issued a complete response letter for the company’s experimental anti-pain medicine.

To View This Article:

Login

Subscribe To Drug Industry Daily